Shattuck Labs (STTK) vs Valneva (VALN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Shattuck Labs (STTK) has outperformed Valneva (VALN) over the past year, gaining 130.8% versus a loss of 44.9%. Over five years, STTK leads with a -70.7% price change compared with -79.1% for VALN. Shattuck Labs is the larger company by market cap ($579.6 million vs $540.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | STTK | VALN |
|---|---|---|
| Share price | $5.78 | $5.70 |
| Market cap | $579.60M | $540.49M |
| 1-day change | +2.12% | -2.90% |
| YTD return | +54.93% | -33.45% |
| 1-year return | +130.82% | -44.88% |
| 5-year return | -70.74% | -79.07% |
| Forward P/E | — | 4.79 |
| EPS (TTM) | $-0.47 | $-2.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.33 | $12.18 |
| 52-week low | $1.70 | $4.75 |
| Distance from 52-week high | -30.67% | -53.20% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +163.55% | +114.91% |
| Average volume | 1.20M | 78.15K |
| Shares outstanding | 100.36M | 94.82M |
| Employees | 40 | 620 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STTK has outperformed VALN by 175.7 percentage points over the past year.
About Shattuck Labs
STTK stock →Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
About Valneva
VALN stock →Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees
STTK vs VALN FAQ
Which is bigger, Shattuck Labs or Valneva?
Shattuck Labs (STTK) is larger, with a market capitalization of $579.60M compared with $540.49M for Valneva (VALN).
Which stock has performed better over the past year, STTK or VALN?
STTK returned +130.82% over the past 12 months, compared with -44.88% for VALN (price return, excluding dividends). Past performance does not predict future results.
Are Shattuck Labs and Valneva in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Shattuck Labs and Biotechnology: Biological Products (No Diagnostic Substances) for Valneva.